David Meek only started work as CEO of France’s mid-sized pharmaceutical company, Ipsen, a couple of weeks ago, but he has already seen his new company gain a positive opinion from Europe’s CHMP for a new cancer product, and the presentation of positive earnings results for the second quarter of 2016.
Meek To Drive M&A At Ipsen, Building On Two Major Launches
France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.